Utilizing in vivo genome-wide CRISPR/Cas9 screens in immunocompetent mouse models to identify novel tumor liabilities and explore mechanisms of resistance to Chimeric Antigen Receptor T-cell therapy
Despite significant advancements in the understanding of cancer and the development of countless novel therapeutic modalities, resistance and relapse remain persistent and pervasive issues across tumor types even in the setting of cutting-edge treatments. The situation is particularly dire for tumor...
Main Author: | Koch, Catherine E. |
---|---|
Other Authors: | Hemann, Michael T. |
Format: | Thesis |
Published: |
Massachusetts Institute of Technology
2024
|
Online Access: | https://hdl.handle.net/1721.1/156275 |
Similar Items
-
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
by: Jiangtao Ren, et al.
Published: (2017-04-01) -
Ex vivo pleural effusion cultures to study chimeric antigen receptor T cell cytotoxicity in an immunocompetent environment
by: Zachary E. Tano, et al.
Published: (2023-11-01) -
CRISPR/Cas9-based genome-wide screening of Dictyostelium
by: Takanori Ogasawara, et al.
Published: (2022-07-01) -
Genetic screens in vivo using the CRISPR/Cas9 system
by: Ellis, Donald Christian
Published: (2017) -
PRODUCTION OF “UNIVERSAL” CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS THROUGH A HIGHLY EFFICIENT CRISPR/CAS9-INDUCED KNOCKOUT OF THE ENDOGENOUS TRAC GENE
by: SCG Lima, et al.
Published: (2023-10-01)